Vicarious Surgical Inc Financials
This page shows Vicarious Surgical Inc (RBOT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Vicarious Surgical Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Vicarious Surgical Inc generates $0.90 in operating cash flow (-$45.1M OCF vs -$50.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Vicarious Surgical Inc's EBITDA was -$48.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.6% from the prior year.
Vicarious Surgical Inc reported -$50.2M in net income in fiscal year 2025. This represents an increase of 20.6% from the prior year.
Cash & Balance Sheet
Vicarious Surgical Inc generated -$45.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 9.8% from the prior year.
Vicarious Surgical Inc held $2.6M in cash against $0 in long-term debt as of fiscal year 2025.
Margins & Returns
Vicarious Surgical Inc's ROE was -509.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 374.5 percentage points from the prior year.
Capital Allocation
Vicarious Surgical Inc invested $33.6M in research and development in fiscal year 2025. This represents a decrease of 16.3% from the prior year.
Vicarious Surgical Inc invested $132K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 26.7% from the prior year.
RBOT Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $8.0M-11.7% | $9.1M-3.9% | $9.4M | N/A | $10.8M-1.1% | $10.9M+9.6% | $10.0M |
| SG&A Expenses | N/A | $3.2M-23.3% | $4.1M-22.1% | $5.3M | N/A | $5.7M+2.8% | $5.6M+11.8% | $5.0M |
| Operating Income | N/A | -$11.5M+14.9% | -$13.5M+14.1% | -$15.7M | N/A | -$17.8M-0.2% | -$17.7M-10.0% | -$16.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$11.1M+16.3% | -$13.2M+14.2% | -$15.4M | N/A | -$17.1M-12.4% | -$15.2M+10.6% | -$17.0M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | $-2.59-2490.0% | $-0.10 |
RBOT Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $19.6M-33.3% | $29.3M-28.2% | $40.9M-25.7% | $55.1M-18.7% | $67.7M-16.0% | $80.6M-13.6% | $93.3M-11.3% | $105.3M |
| Current Assets | $11.6M-23.2% | $15.1M-42.2% | $26.1M-34.3% | $39.7M-23.3% | $51.7M-19.2% | $64.0M-15.7% | $75.9M-12.8% | $87.1M |
| Cash & Equivalents | $2.6M-18.8% | $3.2M-19.1% | $3.9M+50.4% | $2.6M-73.3% | $9.7M+37.7% | $7.1M-65.1% | $20.3M-47.0% | $38.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $9.7M-36.2% | $15.3M-14.4% | $17.8M-15.0% | $21.0M-0.2% | $21.0M-7.5% | $22.7M+5.8% | $21.5M+1.0% | $21.3M |
| Current Liabilities | $3.9M+22.9% | $3.2M-37.7% | $5.1M-35.1% | $7.9M+2.5% | $7.7M-10.9% | $8.6M+19.8% | $7.2M+41.5% | $5.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9.8M-30.1% | $14.1M-38.9% | $23.1M-32.3% | $34.1M-27.0% | $46.7M-19.3% | $57.9M-19.5% | $71.9M-14.5% | $84.0M |
| Retained Earnings | -$246.1M-4.5% | -$235.6M-4.9% | -$224.5M-6.3% | -$211.3M-7.9% | -$195.9M-7.7% | -$182.0M-10.4% | -$164.9M-10.2% | -$149.7M |
RBOT Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.3M+11.0% | -$10.5M+22.7% | -$13.5M-15.0% | -$11.8M+0.2% | -$11.8M+7.1% | -$12.7M-15.1% | -$11.0M+23.8% | -$14.5M |
| Capital Expenditures | N/A | N/A | $0-100.0% | $5K | N/A | N/A | $6K-40.0% | $10K |
| Free Cash Flow | N/A | N/A | -$13.5M-14.9% | -$11.8M | N/A | N/A | -$11.0M+23.8% | -$14.5M |
| Investing Cash Flow | $3.0M-68.8% | $9.7M-34.6% | $14.8M+221.2% | $4.6M-68.1% | $14.4M+3037.0% | -$492K+92.9% | -$7.0M-4727.1% | -$144K |
| Financing Cash Flow | $5.7M+21800.0% | $26K+8.3% | $24K+41.2% | $17K+183.3% | $6K | $0 | $0-100.0% | $2K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RBOT Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -78.5%-21.2pp | -57.3%-12.1pp | -45.2% | N/A | -29.5%-8.4pp | -21.2%-0.9pp | -20.2% |
| Return on Assets | N/A | -37.7%-5.4pp | -32.3%-4.4pp | -28.0% | N/A | -21.2%-4.9pp | -16.3%-0.1pp | -16.2% |
| Current Ratio | 2.97-1.8 | 4.75-0.4 | 5.11+0.1 | 5.05-1.7 | 6.74-0.7 | 7.44-3.1 | 10.57-6.6 | 17.16 |
| Debt-to-Equity | 0.99-0.1 | 1.08+0.3 | 0.77+0.2 | 0.62+0.2 | 0.45+0.1 | 0.39+0.1 | 0.30+0.0 | 0.25 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Vicarious Surgical Inc profitable?
No, Vicarious Surgical Inc (RBOT) reported a net income of -$50.2M in fiscal year 2025.
What is Vicarious Surgical Inc's EBITDA?
Vicarious Surgical Inc (RBOT) had EBITDA of -$48.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Vicarious Surgical Inc's return on equity (ROE)?
Vicarious Surgical Inc (RBOT) has a return on equity of -509.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Vicarious Surgical Inc's free cash flow?
Vicarious Surgical Inc (RBOT) generated -$45.2M in free cash flow during fiscal year 2025. This represents a 9.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Vicarious Surgical Inc's operating cash flow?
Vicarious Surgical Inc (RBOT) generated -$45.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Vicarious Surgical Inc's total assets?
Vicarious Surgical Inc (RBOT) had $19.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Vicarious Surgical Inc's capital expenditures?
Vicarious Surgical Inc (RBOT) invested $132K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Vicarious Surgical Inc spend on research and development?
Vicarious Surgical Inc (RBOT) invested $33.6M in research and development during fiscal year 2025.
What is Vicarious Surgical Inc's current ratio?
Vicarious Surgical Inc (RBOT) had a current ratio of 2.97 as of fiscal year 2025, which is generally considered healthy.
What is Vicarious Surgical Inc's debt-to-equity ratio?
Vicarious Surgical Inc (RBOT) had a debt-to-equity ratio of 0.99 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Vicarious Surgical Inc's return on assets (ROA)?
Vicarious Surgical Inc (RBOT) had a return on assets of -256.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Vicarious Surgical Inc's cash runway?
Based on fiscal year 2025 data, Vicarious Surgical Inc (RBOT) had $2.6M in cash against an annual operating cash burn of $45.1M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Vicarious Surgical Inc's Piotroski F-Score?
Vicarious Surgical Inc (RBOT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Vicarious Surgical Inc's earnings high quality?
Vicarious Surgical Inc (RBOT) has an earnings quality ratio of 0.90x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.